Fertility Hormones, CD4+T Cells and CD8+Tcells In HIV Seropositive Subjects in Onitsha, Nigeria

Oluboyo, A.O\(^1\), Ihejimkpo, A.E\(^1\), Onyenekwe, C.C\(^1\), Oluboyo, B.O\(^2\), A.O\(^1\) Amah, U.K\(^1\), Okwara, J.E\(^1\), Ogenyi, S. I\(^1\), Onyemelukwe\(^1\)

\(^1\)Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, College of Health Sciences, Nnamdi Azikiwe, University, Nnewi Campus, Anambra State, Nigeria
\(^2\)PCR Laboratory, Institute of Human Virology, Nnamdi Azikiwe, University Teaching Hospital, Nnewi, Anambra State, Nigeria

Abstract

Human immunodeficiency Virus (HIV) infection and Acquired immunodeficiency syndrome (AIDS) have become global health concern. The uses of antiretroviral therapy (ART) have been shown to improve health but are associated with a wide array of immunologic, endocrinologic and metabolic abnormalities. This study determined the levels of fertility hormones, CD4 and CD8+Tcells in HIV seropositive subjects and seronegative subjects. A total of one hundred and seventy HIV seropositive subjects were investigated while fifty HIV seronegative subjects served as controls. Eighty-five HIV seropositive subjects were on antiretroviral therapy consisting of three drug combinations (Zidovudine 300mg twice daily; Lamivudine 150mg twice daily; Tenofovir 300mg once daily; Efavirenz 600mg once daily and Stavudine 30mg twice daily for body weight of <60kg or 40mg twice daily for body weight of >60kg). Eighty five HIV seropositive subjects were not on antiretroviral therapy. Fertility hormones (Follicle Stimulating Hormone, Leutinising Hormone, Prolactin and Testosterone) were determined using Enzyme linked immunosorbent assay (ELISA) method. CD4+Tcells and CD8+Tcells were determined using flow cytometry. The serum levels of the fertility hormones in HIV seropositive males on antiretroviral therapy (ART) and those not on ART showed significant reduction (P<0.05) when compared with that of HIV seronegative male control subjects. The serum levels of the hormones in HIV seropositive females on ART and those not on ART showed no significant difference compared with those of HIV seronegative control female subjects. The CD4+T cell counts of HIV seropositive male and female subjects on ART and those not on ART showed significant reduction (P<0.05) when compared with the HIV seronegative control subjects. There was significant increase in the levels of CD8+T cell counts of the HIV seropositive males and females on ART. HIV infection is associated with variations in the male hormonal fertility profiles but without significant effect on women hormonal fertility profiles. However, CD4+Tcells decrease while CD8+T cells increase as HIV/AIDS progresses.

Key words: Fertility hormones, CD4+Tcells, CD8+Tcells, HIV seropositive subjects

INTRODUCTION

Human immunodeficiency Virus (HIV) infection and AIDS have become global health issues of great concern. More than 33 million people around the world are infected with HIV and 3.4 million Nigerians are living with HIV and 58.0 % among these are women. It has been reported that infection by HIV/AIDS and its antiretroviral therapy are associated with a wide array of endocrine and metabolic abnormalities which include adrenal insufficiency, thyroid, hypogonadism and hypopituitarism (Dobs et al., 1988; Dobs et al, 1996; Petrovsky et al., 1995). Although, treatment with antiretroviral drugs increase the life expectancy of people infected with HIV, the virus affects the body’s ability to produce and maintain hormone levels. Conde et al, (2009) reported that some drugs that are used to treat HIV related conditions also affect hormone levels. It has also been shown that the HIV infection is associated with altered fertility hormone levels while the antiretroviral therapy may have no effect on the fertility hormones (Ogunlahunshi et al., 2011). HIV/AIDS also have effects on the immune system. In fact, hypogonadism especially lower testosterone levels have been correlated with weight loss and lower CD4 cell counts (Highleyman, 2010). HIV infects primarily vital cells in the human immune system such as helper T cells (CD4+Tcells), macrophages and dendritics cells (Cunnigham et al., 2010). After initial infection of the human host, the pace of immunodeficiency development, susceptibility to infection and malignancies become manifest and are generally associated with the rate of CD4+ declines (Mandy, 2009). The rate of CD4+ decline varies considerably from person to person and is not constant throughout the stages of HIV infection. CD4 T-cells is the primary but not the only leukocyte that may be infected with HIV (Mandy, 2009). The absolute CD4+Tcell counts provides a powerful laboratory measurement of predicting, staging and monitoring disease progression and response to treatment in HIV- infected individuals (Turner et al., 1994;
Fertility hormones, CD4 and CD8+T cells in HIV seropositive subjects

O luboyo et al, 2006) but there are some CD8+T cells that suppress or regulate the ongoing immune responses (Davenport and Petravic, 2010). These subsets of CD8+T cells (cytotoxic T-lymphocytes) have the capacity of mediating the lysis of infected autologous cells (Cunningham et al, 2010).

Thus, the study set to determine the fertility hormones, CD4+T cells and CD8+T cells in HIV seropositive subjects to see if there are variations in the hormonal fertility profiles in Onitsha, Nigeria.

MATERIALS AND METHODS

The study subjects comprised 170 HIV seropositive adults attending a voluntary counseling and testing (VCT) clinic at Onitsha, Anambra State, Nigeria and 50 seronegative subjects served as control. Eighty-five (85) HIV seropositive subjects were on antiretroviral therapy consisting of three drug combinations (Zidovudine 300mg twice daily; Lamivudine 150mg twice daily; Tenoforvir 300mg once daily; Efavirenz 600mg once daily and Stavudine 30mg twice daily for body weight of <60kg or 40mg twice daily for body weight of >60kg) while the remaining eighty five (85) subjects were not on ART. Adequate precautions for collection and handling of blood specimen were observed throughout the research work. The blood specimens for CD4+T cells and CD8+T cells were collected into Ethylenediaminetetraaceticacid (EDTA) anticoagulated bottles and were analyzed immediately. The CD4+ and CD8+T cell counts were determined using Partec cyflow counter (Partec GMBH, Germany). The blood specimens for the fertility hormones were collected into plain specimen containers without anticoagulant. The samples for hormonal assay were allowed to clot and retracted before centrifugation at 1200 rpm for 5minutes using a bench centrifuge. The serum was collected and preserved in a freezer at -20°C until analysis. The hormones were determined using Enzyme immunoassay kits (Diagnostic Automation) and the concentrations of the hormones were determined using Enzyme linked immunoassay (ELISA) reader (STAT Fax – 2100 machine from Awareness Technology, Germany).

Statistical analysis of data

The mean and the standard deviations of the data were obtained using Windows software package for Social Sciences (SPSS) version16. T-test and Analysis of Variance (ANOVA) were used to compare the mean and the standard deviations of the results and P<0.05 was taken as the level of significance.

RESULTS

The mean levels of fertility hormones, CD4 + T cells and CD8 +T cells in HIV seropositive subjects and controls are shown in table 1. There were significant decreases in the mean levels of Follicle stimulating hormones (FSH), Leutinising hormone (LH), Prolactin, Testosterone and CD4+ T cells of HIV subjects when compared with the controls. However, there was a significant increase in the mean CD8 +T cells in HIV seropositive subjects compared with the controls. Table 2 shows the mean levels of fertility hormones, CD4 + T cells and CD8 +T cells in HIV seropositive male subjects and male controls. Furthermore, there were significant decreases in the mean levels of Follicle stimulating hormones (FSH), Leutinising hormone (LH), Prolactin, Testosterone and CD4+ T cells of the HIV seropositive male subjects when compared with the male controls.

**Table 1 :**

Fertility hormones, CD4 + T cells and CD8 +T cells in HIV Subjects on drug therapy, those not on drug therapy and Control subjects

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HIV Subjects on ART</th>
<th>HIV Subjects not on ART</th>
<th>Control</th>
<th>F-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSH (mIU/ml)</td>
<td>5.40±2.18</td>
<td>5.84± 2.12</td>
<td>6.88±1.45</td>
<td>8.25</td>
<td>0.00*</td>
</tr>
<tr>
<td>LH (mIU/ml)</td>
<td>8.68±4.63</td>
<td>8.39±3.55</td>
<td>9.73±2.85</td>
<td>7.20</td>
<td>0.02*</td>
</tr>
<tr>
<td>Prolactin (ng/ml)</td>
<td>6.23±2.30</td>
<td>6.53±2.26</td>
<td>7.63±1.99</td>
<td>7.58</td>
<td>0.00*</td>
</tr>
<tr>
<td>Testosterone (ng/ml)</td>
<td>2.29±1.70</td>
<td>2.72±0.95</td>
<td>6.17±0.46</td>
<td>8.43</td>
<td>0.00*</td>
</tr>
<tr>
<td>CD4 +Tcells (cells/µl)</td>
<td>397.95±186.52</td>
<td>442.96±1223.00</td>
<td>878.86±195.81</td>
<td>79.64</td>
<td>0.00*</td>
</tr>
<tr>
<td>CD8 +Tcells (cells/µl)</td>
<td>872.02±242.11</td>
<td>872.76±216.19</td>
<td>440.30±111.17</td>
<td>35.98</td>
<td>0.00*</td>
</tr>
</tbody>
</table>

*Statistically significant at P<0.05

**Table 2 :**

Fertility Hormones, CD4 + T cells and CD8 +T cells of HIV seropositive and seronegative male subjects.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HIV Male Subjects on ART</th>
<th>HIV Male Subjects not on ART</th>
<th>Control Males</th>
<th>F-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSH (mIU/ml)</td>
<td>5.33±2.25</td>
<td>3.41±2.01</td>
<td>3.00±2.27</td>
<td>7.359</td>
<td>0.00*</td>
</tr>
<tr>
<td>LH (mIU/ml)</td>
<td>6.70±4.35</td>
<td>7.08±3.18</td>
<td>9.95±2.27</td>
<td>8.868</td>
<td>0.00*</td>
</tr>
<tr>
<td>Prolactin (ng/ml)</td>
<td>5.45±2.26</td>
<td>6.15±2.26</td>
<td>6.17±0.46</td>
<td>7.672</td>
<td>0.00*</td>
</tr>
<tr>
<td>TESTOSTERONE (ng/ml)</td>
<td>4.28±1.70</td>
<td>5.00±1.72</td>
<td>6.17±1.67</td>
<td>9.433</td>
<td>0.00*</td>
</tr>
<tr>
<td>CD4 +Tcells (cells/µl)</td>
<td>337.48±127.22</td>
<td>402.55±181.12</td>
<td>937.60±189.67</td>
<td>97.952</td>
<td>0.00*</td>
</tr>
<tr>
<td>CD8 +Tcells (cells/µl)</td>
<td>872.02±242.11</td>
<td>916.25±203.37</td>
<td>447.30±120.98</td>
<td>37.540</td>
<td>0.00*</td>
</tr>
</tbody>
</table>

*Statistically significant at P<0.05
There was also a significant increase in the mean CD8+ T cells in HIV seropositive subjects compared with the male controls. Table 3 shows the mean levels of fertility hormones, CD4+ T cells and CD8+ T cells in HIV seropositive female subjects and control females. There were no significant differences in the fertility hormones but there was a significant decrease of CD4+ T cells and a significant increase of CD8+ T cells levels of HIV seropositive female subjects compared with the control females.

**DISCUSSION**

It has been reported that infection by HIV/AIDS and the use of antiretroviral therapy are associated with a wide array of endocrine and metabolic abnormalities (Highleyman, 2010). There was a significant decrease in the mean serum levels of FSH, LH, prolactin and testosterone in HIV seropositive male subjects when compared with the HIV seronegative control subjects. This finding supports the report of Highleyman (2010). He stated that hypogonadism occurred in a majority of HIV seropositive men. The decrease may be as a result of disturbances in hypothalamic-pituitary-gonadal axis or due to metabolic abnormalities associated with HIV/AIDS. The low testosterone in HIV seropositive patients may result to a variety of symptoms including wasting, fatigue, anaemia, depression and loss of libido which is common to HIV seropositive patients (Highleyman, 2010) especially those with symptomatic HIV diseases.

Furthermore, no significant difference was found in the levels of fertility hormones in HIV seropositive females and HIV seronegative female control subjects. Although, previous studies on the impact of HIV on fertility hormones in women have been inconsistent, our findings are in support of those who suggested that HIV has little or no impact on menstrual function (Shah et al., 1996; Ellerbrock et al., 1996). They reported no significant differences in rates of amenorrhea, sparse or heavy menstruation or menstrual cramps between HIV seropositive and seronegative women. However, Ogundahunsi et al (2011) detected a significant decrease in the levels of fertility hormones in HIV women. They reported that treatment with ART improved lives, reduced the risk of opportunistic infections but do not have significant influence on the fertility hormones of HIV infected men and women.

This study also observed a significant decrease in CD4+T cells count and significant increase in the mean levels of CD8+ T cells count in HIV seropositive male and female subjects when compared with the HIV seronegative control subjects. This trend has been shown to be common to all HIV seropositive patients because CD4+Tcells are being attacked by the virus while CD8+Tcells are released to fight the virus (Oluwoye et al., 2006; Schelleus et al., 2008). Although, Pohling et al (2010) stated that while antiretroviral suppression of HIV in chronic infection reduces HIV-specific CD8+ T cell response magnitude in the short term, it had no significant effect on response character over periods up to 9 years. However, a recent finding has reported that a subset of CD4+ white blood cells invaded by HIV may control the course of the disease (Cohen, 2013).

We conclude that HIV infection is associated with variations in the male hormonal fertility profiles but without significant effect on women hormonal fertility profiles. However, CD4+Tcells decrease while CD8+T cells increase as HIV/AIDS progresses.

**References**


Highleyman L. (2010): Inflammation, immune activation, and HIV. Winter-Spring;22(2):12-26


Fertility hormones, CD4 and CD8+T cells in HIV seropositive subjects


Pohling, J., Zipperlen, K., Hollett, N.A., Gallant, M.E., Grant, M. D. (2010): Human immunodeficiency virus type 1-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy. BMC Infectious Diseases, 10 (129) 1-10.


